Investigational Drug Information for CBP-307
✉ Email this page to a colleague
What is the drug development status for CBP-307?
CBP-307 is an investigational drug.
There have been 4 clinical trials for CBP-307.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 27th 2019.
The most common disease conditions in clinical trials are Autoimmune Diseases, Ulcer, and Colitis, Ulcerative. The leading clinical trial sponsors are Suzhou Connect Biopharmaceuticals, Ltd., Nucleus Network Ltd, and Tigermed Consulting Co., Ltd.
There are ten US patents protecting this investigational drug.
Summary for CBP-307
| US Patents | 10 |
| International Patents | 0 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 16 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-02-27) |
| Vendors | 6 |
Recent Clinical Trials for CBP-307
| Title | Sponsor | Phase |
|---|---|---|
| A Study On Human Mass Balance And Biotransformation | Suzhou Connect Biopharmaceuticals, Ltd. | Phase 1 |
| A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects | Suzhou Connect Biopharmaceuticals, Ltd. | Phase 1 |
| A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) | Suzhou Connect Biopharmaceuticals, Ltd. | Phase 2 |
Clinical Trial Summary for CBP-307
Top disease conditions for CBP-307
Top clinical trial sponsors for CBP-307
US Patents for CBP-307
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CBP-307 | ⤷ Start Trial | AMPK activators | Kallyope Inc | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | AMPK activators | Kallyope Inc | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | Compounds active towards nuclear receptors | Nuevolution AS | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | Compounds active towards nuclear receptors | Nuevolution AS | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | Thienopyrrole compounds | Gilead Sciences Inc | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | Compounds active towards nuclear receptors | Nuevolution AS , Almirall SA | ⤷ Start Trial |
| CBP-307 | ⤷ Start Trial | Compounds active towards nuclear receptors | Nuevolution AS , Almirall SA | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
